Fabre-Kramer Pharmaceuticals is a pharmaceutical company that specializes in the development of psychotropic drugs. Products in their current development pipeline include gepirone and FKB01MD for major depression, gepirone and FKW00GA for social anxiety disorder,[1] gepirone for hypoactive sexual desire disorder, FKF02SC for schizophrenia, and FKK01PD for Parkinson's disease.[2]
The company has also conducted clinical studies on a gepirone extended release formulation for major depression.[3][4][5]
In 2007, Fabre-Kramer Pharmaceuticals along with GlaxoSmithKline (GSK) received a 'not approvable' letter from the US Food and Drug Administration, for a gepirone extended release drug, an antidepressant treatment for adults.[6]
External links
References
- Pipeline – Fabre-Kramer Pharmaceuticals, Inc. retrieved 2023-03-30^
- Product Pipeline Fabre Kramer Pharmaceuticals, retrieved 2011-10-16^
- The Effect of Major Depression on Sexual Function in Women J Sex Med, August 2011^
- Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain--a post hoc analysis J Sex Med, September 2011^
- Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women J Sex Med, May 2011^
- Anna Lewcock. GSK, Fabre-Kramer lose out on antidepressant outsourcing-pharma.com, November 5, 2007, retrieved 2020-05-11^